| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
One of the nation’s leading academic medical centers, Robert Wood Johnson University Hospital provides state-of-the-art care across the full range of health care services. Specialties include cardiac care from screening to heart surgery and transplantation, cancer care, emergency medicine, pediatrics and maternal-fetal medicine.
Sebastian International Inc is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acusphere, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Cambridge, MA. To find more information about Acusphere, Inc., please visit www.acusphere.com
HemCare Health Services (“HHS”) is a Health Information Exchange company. HHS operates a single unified platform enabling the ability to request and retrieve medical information and records while meeting all of today`s Security & Compliance demands for HIPAA, PIPEDA and PHIPA. Through RecordsBank.org, the Company offers an easy to use online portal to our centralized System for Patients, Lawyers & Insurers to Retrieve and Access Medical Records 24 hours a day, 7 days a week. The centralized system and portal for Patients, Lawyers & Insurers to Retrieve and Access Medical Records is a cloud-based PIPEDA & HIPAA compliant network of Providers and Record Requestors. Utilizing a secure platform, providers are able to securely exchange records electronically with third-party requestors. Health care providers with proper authorization can also share records with each other. HHS` Electronic health information exchange (HIE) allows doctors, nurses, pharmacists, other health care providers and patients to appropriately access and securely share a patient`s vital medical information electronically—improving the speed, quality, safety and cost of patient care. Despite the widespread availability of secure electronic data transfer, most Americans` medical information is stored on paper—in filing cabinets at various medical offices, or in boxes and folders in patients` homes. When that medical information is shared between providers, it happens by mail, fax or—most likely—by patients themselves, who frequently carry their records from appointment to appointment. While electronic health information exchange cannot replace provider-patient communication, it can greatly improve the completeness of patient`s records, (which can have a big effect on care), as past history, current medications and other information is jointly reviewed during visits. Appropriate, timely sharing of vital patient information can better inform decision making at the point of care and allow providers to • Avoid readmissions • Avoid medication errors • Improve diagnoses • Decrease duplicate testing • Reduce cost and administration If a practice has successfully incorporated faxing patient information into their business process flow, they might question why they should transition to electronic health information exchange. Many benefits exist with information exchange regardless of the means of which it is transferred. However, the value of electronically exchanging is the standardization of data. Once standardized, the data transferred can seamlessly integrate into the recipients` Electronic Health Record (EHR), further improving patient care. For example: • If laboratory results are received electronically and incorporated into a provider`s EHR, a list of patients with diabetes can be generated. The provider can then determine which of these patients have uncontrolled blood sugar and schedule necessary follow-up appointments. There are currently three key forms of health information exchange that HHS facilitates: • Directed Exchange – ability to send and receive secure information electronically between care providers to support coordinated care • Query-based Exchange – ability for providers to find and/or request information on a patient from other providers, often used for unplanned care • Consumer Mediated Exchange – ability for patients to aggregate and control the use of their health information among providers